Recently, Jianfan Biology (300529.SZ), a leading hemoperfusion device company, released its 2021 annual report. The company achieved revenue of 2.675 billion yuan last year, a year-on-year increase of 37.15%, and net profit attributable to the parent was 1.197 billion yuan, a year-on-year increase of 36.74%. Since its listing on the Growth Enterprise Market in 2016, the performance of listed companies has maintained steady growth.
Although the revenue of other products has grown rapidly, Jianfan Bio is still heavily dependent on the major single product of hemoperfusion, which accounts for nearly 90% of the revenue. From 2018 to 2020, the contribution of blood perfusion devices to the company’s revenue was 90.98%, 90.66% and 88.67%, respectively. Excessive reliance on a single product also increases the operational risk of Jianfan Bio.
Source of cover image: Photo Network-401415947
Copyright Notice
1This article is an original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, excerpting, copying or creating mirror images, etc. Violators will be held accountable.
3Copyright cooperation telephone: 021-60900099.